



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/625,357	07/23/2003	Ryland F. Young	HQ-P01886US2	8574

26271 7590 12/01/2006  
FULBRIGHT & JAWORSKI, LLP  
1301 MCKINNEY  
SUITE 5100  
HOUSTON, TX 77010-3095

EXAMINER

JOIKE, MICHELE K

ART UNIT PAPER NUMBER

1636

DATE MAILED: 12/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. 10/625,357		Applicant(s) YOUNG ET AL.	
Examiner Michele K. Joike, Ph.D.		Art Unit 1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 10 September 2006.
- 2a) ☐ This action is FINAL.
- 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-12, 51 and 52 is/are pending in the application.
  - 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-12, 51 and 52 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 23 July 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
    - a) ☐ All   b) ☐ Some \* c) ☐ None of:
      - 1. ☐ Certified copies of the priority documents have been received.
      - 2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
      - 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)  
 Paper No(s)/Mail Date 07/23/03
- 4) ☐ Interview Summary (PTO-413)  
 Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Election/Restrictions***

Applicant's election without traverse of Group I, claims 1-12, 51 and 52 in the reply filed on September 19, 2006 is acknowledged.

### ***Specification***

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01. See page 53, example 1.

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-6, 12 and 52 are rejected under 35 U.S.C. 102(b) as being anticipated by Maratea et al.

Applicants claim a method of screening for a bacterial nucleic acid sequence that encodes a polypeptide for a single-gene lysis polypeptide comprising contacting bacteria with a lysis polypeptide; selecting for bacterial survivors of cell lysis caused by the lysis polypeptide that survive lysis by having

Art Unit: 1636

the bacterial nucleic acid sequence that encodes a polypeptide making cells resistant to lysis by the lysis polypeptide; and mapping and isolating the candidate bacterial nucleic acid sequence, wherein the mapped sequence corresponds to the nucleic acid sequence which encodes the target polypeptide, involved in cell wall synthesis.

The claims further limit the invention to wherein contacting the bacteria with the lysis polypeptide comprises transforming bacteria with a vector comprising a nucleic acid sequence that encodes a single-gene lysis polypeptide, wherein its expression is induced, and the lysis polypeptide is mutated, and is the E polypeptide.

Maratea et al (Gene 40: 39-46, 1985, specifically materials & methods (b) and (c), pages 41, 44 and 45, and figures 1 and 2) teach a method of screening for a bacterial nucleic acid sequence that encodes a polypeptide for a single-gene lysis polypeptide. The single-gene lysis polypeptide is the *E* gene from bacteriophage  $\Phi$ X174. Mapping of the candidate nucleic acid sequences that conferred resistance to the E polypeptide revealed mutants of the *slyD* gene, which is involved in cell wall synthesis. The wild type *E* gene and mutants of the *E* gene are inserted into vectors (see Table 1), as *E lacZ* fusions for expression and determination of  $\beta$ -gal activity. The *slyD* gene was characterized by mapping and testing of *slyD* mutants for sensitivity to the *E lacZ* fusions. Also, testing for the recessiveness of *slyD* was performed.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 7-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Maratea et al in view of Shimol et al.

Applicants claim determining the characteristics of the bacterial nucleic acid sequence by gel electrophoresis. They also insert the mapped bacterial nucleic acid sequence in an expression vector to produce a polypeptide, isolate the polypeptide and determine the characteristics of the polypeptide by electrophoresis.

Art Unit: 1636

Maratea et al teach all of the limitations as described above. However, Maratea et al do not teach determining the characteristics of the bacterial nucleic acid sequence by gel electrophoresis, inserting the mapped bacterial nucleic acid sequence in an expression vector to produce a polypeptide, isolating the polypeptide and determining the characteristics of the polypeptide by electrophoresis.

Shimol et al (J. Bac. 180(13): 3381-3387, 1998, specifically, pp. 3382-3383 and 3387) teach identifying a cell wall protein (Sed1p) required for lytic enzyme resistance. Sed1p is purified and characterized by amino acid sequencing, SDS PAGE, Western blotting and PNGase digestion. The SED1 gene was characterized by electrophoresis and then inserted into a plasmid, which was transformed into diploid cells. Sed1p was isolated by RPI treatment and further purified by reverse-phase chromatography. Amino acid sequencing was performed again.

The ordinary skilled artisan, desiring to determine the characteristics of the bacterial nucleic acid sequence and insert the bacterial nucleic acid sequence in an expression vector to produce a polypeptide, would have been motivated to combine the teachings of Maratea et al teaching a method of screening for a bacterial nucleic acid sequence that encodes a polypeptide for a single-gene lysis polypeptide comprising contacting bacteria with a lysis polypeptide; selecting for bacterial survivors of cell lysis caused by the lysis polypeptide that survive lysis by having the bacterial nucleic acid sequence that encodes a polypeptide making cells resistant to lysis by the lysis polypeptide; and mapping

Art Unit: 1636

and isolating the candidate bacterial nucleic acid sequence, with the teachings of Shimol et al, teaching characterizing the SED1 gene and protein because Sed1p is required for lytic enzyme resistance. It would have been obvious to one of ordinary skill in the art to use SED1 for producing a protein that makes cells resistant to a lysis polypeptide because Shimol et al teach that Sed1p is a major structural wall protein and plays a role in cell defense mechanisms, including protection against cell lysis. Given the teachings of the prior art and the level of the ordinary skilled artisan at the time of the applicant's invention, it must be considered, absent evidence to the contrary, that said skilled artisan would have had a reasonable expectation of success in practicing the claimed invention.

Claim 51 is rejected under 35 U.S.C. 103(a) as being unpatentable over Maratea et al in view of Boyle et al.

Applicants claim the bacterial nucleic acid sequence as *mraY*.

Maratea et al teach all of the limitations as described above. However, Maratea et al do not teach the bacterial acid sequence as being *mraY*.

Boyle et al (J. Bac. 180(23): 6429-6432, 1998, specifically, Abstract and p. 6430) teach *mraY* as encoding a cell wall synthesis protein.

The ordinary skilled artisan, desiring to use *mraY*, would have been motivated to combine the teachings of Maratea et al teaching a method of screening for a bacterial nucleic acid sequence that encodes a polypeptide for a single-gene lysis polypeptide comprising contacting bacteria with a lysis polypeptide; selecting for bacterial survivors of cell lysis caused by the lysis polypeptide that survive lysis by having the bacterial nucleic acid sequence that

Art Unit: 1636

encodes a polypeptide making cells resistant to lysis by the lysis polypeptide; and mapping and isolating the candidate bacterial nucleic acid sequence, with the teachings of Boyle et al, teaching *mraY* as encoding a cell wall synthesis protein, because *mraY* is an essential gene required for cell wall growth. It would have been obvious to one of ordinary skill in the art to use *mraY* because Boyle et al teach that cells depleted of *mraY* lyse. Given the teachings of the prior art and the level of the ordinary skilled artisan at the time of the applicant's invention, it must be considered, absent evidence to the contrary, that said skilled artisan would have had a reasonable expectation of success in practicing the claimed invention.

***Allowable Subject Matter***

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michele K. Joike, Ph.D. whose telephone number is 571-272-5915. The examiner can normally be reached on M-F, 9:00-6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.



Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michele K Joike, Ph.D.  
Examiner  
Art Unit 1636

  
DAVID GUZO  
PRIMARY EXAMINER